⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 29, 2024Open Access

Supplemental Figure 2 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

Nicholas J. Hornstein Mohammad A. Zeineddine Betul Beyza Gunes Andrew J. Pellatt Mark Knafl Haifeng Zhu Anneleis F. Willett Abdelrahman Yousef Suyu Liu Ryan Sun P. Andrew Futreal Scott E. Woodman Melissa W. Taggart Michael J. Overman Daniel M. Halperin Kanwal Raghav John Paul Shen

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Figure 2: Representative Pathology Images A,B: Representative images from patient tumor biopsies large mucin deposits and minimal cellularity. Infiltrating lymphocytes are notable in both images.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hornstein et al. (2024) studied this question.

synapsesocial.com/papers/68e67f58b6db643587608588 https://doi.org/10.1158/2767-9764.25922598

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Figure 2 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma2024
2TABLE 1 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma2024
3TABLE 1 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma2024
4Data from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma2024
5Supplementary Data from Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinoma2024